Combined effects of senexin B and antitumour agents on neuroblastoma and glioblastoma cell lines
- 作者: Mazur D.V.1, Pogodaeva S.S.2, Kuchur O.A.1,2, Miletina O.O.2, Rezekina A.I.1, Petrosyan E.G.1, Rudik D.A.1, Ivanova Е.I.1, Shtil А.А.1,3, Antipova N.V.1,4
-
隶属关系:
- Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, RAS
- ITMO University
- N.N. Blokhin National Medical Research Centre for Oncology
- National Research University “Higher School of Economics”
- 期: 卷 51, 编号 3 (2025)
- 页面: 461-468
- 栏目: ОБЗОРНАЯ СТАТЬЯ
- URL: https://jdigitaldiagnostics.com/0132-3423/article/view/686964
- DOI: https://doi.org/10.31857/S0132342325030091
- EDN: https://elibrary.ru/KQNWWQ
- ID: 686964
如何引用文章
详细
Neurogenic tumors such as neuroblastoma and glioblastoma are highly heterogeneous and particularly aggressive: they are characterized by rapid growth, metastasis and resistance to treatment. Both tumors exhibit MYCN oncogene copy-number disruption, impaired gene transcription, and overall high transcriptional deregulation. In this study, we evaluated the survival of glioblastoma and neuroblastoma cells and performed real-time PCR analysis to assess the change in expression of MYCN, HAND2, PHOX2A, and PHOX2B oncogenes after exposure to senecin B in combination with temozolomide and the potential therapeutic agent 10058-F4. As a result, a trend of increased PHOX2B gene expression and decreased PHOX2A gene expression after drug exposure was observed in one of the neuroblastoma lines and both glioblastoma lines, an increase in MYCN and HAND2 gene expression was also observed. Viability tests showed that substance 10058-F4 was effective against neuroblastoma line but not glioblastoma lines. However, senexin B enhanced the inhibitory effect of 10058-F4 on glioblastoma cell lines and also enhanced the effect of temozolomide on the T98G cell line.
全文:

作者简介
D. Mazur
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, RAS
Email: nadine.antipova@gmail.com
俄罗斯联邦, ul. Miklukho-Maklaya 16/10, Moscow, 117997
S. Pogodaeva
ITMO University
Email: nadine.antipova@gmail.com
俄罗斯联邦, Kronverksky prosp. 49, liter A, St. Petersburg, 197101
O. Kuchur
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, RAS; ITMO University
Email: nadine.antipova@gmail.com
俄罗斯联邦, ul. Miklukho-Maklaya 16/10, Moscow, 117997; Kronverksky prosp. 49, liter A, St. Petersburg, 197101
O. Miletina
ITMO University
Email: nadine.antipova@gmail.com
俄罗斯联邦, Kronverksky prosp. 49, liter A, St. Petersburg, 197101
A. Rezekina
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, RAS
Email: nadine.antipova@gmail.com
俄罗斯联邦, 117997 Москва, улица Миклухо-Маклая, 16/10
E. Petrosyan
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, RAS
Email: nadine.antipova@gmail.com
俄罗斯联邦, ul. Miklukho-Maklaya 16/10, Moscow, 117997
D. Rudik
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, RAS
Email: nadine.antipova@gmail.com
俄罗斯联邦, ul. Miklukho-Maklaya 16/10, Moscow, 117997
Е. Ivanova
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, RAS
Email: nadine.antipova@gmail.com
俄罗斯联邦, ul. Miklukho-Maklaya 16/10, Moscow, 117997
А. Shtil
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, RAS; N.N. Blokhin National Medical Research Centre for Oncology
Email: nadine.antipova@gmail.com
俄罗斯联邦, ul. Miklukho-Maklaya 16/10, Moscow, 117997; Kashirskoye shosse 23, Moscow, 115522
N. Antipova
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, RAS; National Research University “Higher School of Economics”
编辑信件的主要联系方式.
Email: nadine.antipova@gmail.com
俄罗斯联邦, ul. Miklukho-Maklaya 16/10, Moscow, 117997; ul. Profsoyuznaya 33/4, Moscow, 101000 Russia
参考
- Boeva V., Louis-Brennetot C., Peltier A., Durand S., Pierre-Eugène C., Raynal V., Etchevers H.C., Thomas S., Lermine A., Daudigeos-Dubus E., Geoerger B., Orth M.F., Grünewald T.G.P., Diaz E., Ducos B., Surdez D., Carcaboso A.M., Medvedeva I., Deller T., Janoueix-Lerosey I. // Nat. Genet. 2017. V. 49. P. 1408–1413. https://doi.org/10.1038/ng.3921
- Jacob F., Salinas R.D., Zhang D.Y., Nguyen P.T.T., Schnoll J.G., Wong S.Z.H., Thokala R., Sheikh S., Saxena D., Prokop S., Liu D.-A., Qian X., Petrov D., Lucas T., Chen H.I., Dorsey J.F., Christian K.M., Binder Z.A., Nasrallah M., Song H. // Cell. 2020. V. 180. P. 188–204. https://doi.org/10.1016/j.cell.2019.11.036
- Karadkhelkar N.M., Lin M., Eubanks L.M., Janda K.D. // J. Am. Chem. Soc. 2023. V. 145. P. 3259– 3269. https://pubs.acs.org/doi/10.1021/jacs.2c12732
- Müller I., Larsson K., Frenzel A., Oliynyk G., Zirath H., Prochownik E.V., Westwood N.J., Henriksson M.A. // PLoS One. 2014. V. 9. P. e97285. https://doi.org/10.1371/journal.pone.0097285
- Bjerke L., Mackay A., Nandhabalan M., Burford A., Jury A., Popov S., Bax D.A., Carvalho D., Taylor K.R., Vinci M., Bajrami I., McGonnell I.M., Lord C.J., Reis R.M., Hargrave D., Ashworth A., Workman P., Jones C. // Cancer Discov. 2013. V. 3. P. 512–519. https://doi.org/10.1158/2159-8290.CD-12-0426
- Hodgson J.G., Yeh R.-F., Ray A., Wang N.J., Smirnov I., Yu M., Hariono S., Silber J., Feiler H.S., Gray J.W., Spellman P.T., Vandenberg S.R., Berger M.S., James C.D. // Neuro Oncol. 2009. V. 11. P. 477–487. https://doi.org/10.1215/15228517-2008-113
- Čančer M., Drews L.F., Bengtsson J., Bolin S., Rosén G., Westermark B., Nelander S., Forsberg-Nilsson K., Uhrbom L., Weishaupt H., Swartling F.J. // Cell Death Dis. 2019. V. 10. P. 881. https://doi.org/10.1038/s41419-019-2120-1
- Wang B., Wu Z.-H., Lou P.-Y., Chai C., Han S.-Y., Ning J.-F., Li M. // Cell Oncol. 2019. V. 42. P. 783–799. https://doi.org/10.1007/s13402-019-00461-z
- Liang J., Chen M., Hughes D., Chumanevich A.A., Altilia S., Kaza V., Lim C.-U., Kiaris H., Mythreye K., Pena M.M., Broude E.V., Roninson I.B. // Cancer Res. 2018. V. 78. P. 6594–6606. https://doi.org/10.1158/0008-5472.can-18-1583
- Sharko A.C., Lim C.-U., McDermott M.S.J., Hennes C., Philavong K.P., Aiken T., Tatarskiy V.V., Roninson I.B., Broude E.V. // Cells. 2021. V. 10. P. 144. https://doi.org/10.3390/cells10010144
- Ding X., Sharko A.C., McDermott M.S.J., Schools G.P., Chumanevich A., Ji H., Li J., Zhang L., Mack Z.T., Sikirzhytski V., Shtutman M., Ivers L., O’Donovan N., Crown J., Győrffy B., Chen M., Roninson I.B., Broude E.V. // Proc. Natl. Acad. Sci. USA. 2022. V. 119. P. e2201073119. https://doi.org/10.1073/pnas.2201073119
- Zaatiti H., Abdallah J., Nasr Z., Khazen G., Sandler A., Abou-Antoun T.J. // Int. J. Oncol. 2018. V. 52. P. 787– 803. https://doi.org/10.3892/ijo.2018.4236
- Mercatelli D., Balboni N., Palma A., Aleo E., Sanna P.P., Perini G., Giorgi F.M. // Biomolecules. 2021. V. 52. P. 177. https://doi.org/10.3390/biom11020177
- Moody C.L., Wheelhouse R.T. // Pharmaceuticals (Basel). 2014. V. 7. P. 797–838. https://doi.org/10.3390/ph7070797
- McDermott M.S.J., Chumanevich A.A., Lim C.-U., Liang J., Chen M., Altilia S., Oliver D., Rae J.M., Shtutman M., Kiaris H., Győrffy B., Roninson I.B., Broude E.V. // Oncotarget. 2017. V. 8. P. 12558–12575. https://doi.org/10.18632/oncotarget.14894
- Li J., Hilimire T.A., Liu Y., Wang L., Liang J., Gyorffy B., Sikirzhytski V., Ji H., Zhang L., Cheng C., Ding X., Kerr K.R., Dowling C.E., Chumanevich A.A., Mack Z.T., Schools G.P., Lim C.-U., Ellis L., Zi X., Chen M. // J. Clin. Invest. 2024. V. 134. P. e176709. https://doi.org/10.1172/jci176709
补充文件
